Sage Journals: Discover world-class research

Abstract

Objective: To determine whether the complex strategy of lipid measurements for the detection of patients with high blood cholesterol levels proposed by the first Expert Panel of the National Cholesterol Education Panel (NCEP) could be simplified without significant loss of accuracy. Design: Decision-analysis-based model of competing case detection strategies as com pared with the NCEP strategy. A Markov model was used to estimate numbers of people treated over ten years as a result of the different classification strategies. Data sources: Conditional probabilities for the decision trees were derived from cholesterol distributions in national population-based surveys. Parameters for the Markov model were from published major epidemiologic studies and clinical trials. Main outcome measures: Misclassification to treatment vs non-treatment as a continuous function of the distribution of true low-density lipoprotein (LDL). Results : A simplified strategy was designed that screens high-risk persons with two LDL measurements and low-risk people with one cholesterol measurement followed by two LDL measurements if the initial value is high. This algorithm requires 37% fewer measurements to classify a population. The overall accuracy of classification to treatment based on the NCEP I cutoff points is high, with a positive predictive value of 95% and a negative predictive value of 87% (relative to 97% and 80%, respectively, for the NCEP I protocol). This strategy is very similar to published NCEP II guidelines. A strategy that recommends an LDL determination for everyone, as a recent NIH consensus panel sug gested, also significantly reduces the number of measurements required by 48%. The positive predictive value is 93%, vs 97% for the NCEP I protocol. The negative predictive value is 92%, vs 80% for the NCEP I. Conclusions: The complex measurement strategy initially proposed in the NCEP I guidelines did not improve accuracy of classification over the simpler and more convenient strategies that the authors evaluated and that have been substantially adopted in the NCEP II guidelines. Key words: mathematical models; laboratory measure ment; hyperlipidemia; cost-effectiveness analysis; lipids. (Med Decis Making 1994;14:357- 368)

Get full access to this article

View all access options for this article.

References

The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988 ;148:36-69.

Shea S. , Gemson DH , Mossel P. Management of high blood cholesterol by primary care physicians: diffusion of the National Cholesterol Education Program Adult Treatment Panel Guidelines . J Gen Intern Med. 1990;5:327-34.

Schectman JM , Elinsky EG , Bartman BA Primary care clinician compliance with cholesterol treatment guidelines. J Gen Intern Med. 1991 ;2:121-5.

National Institutes of Health Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease, NIH Consensus Development Panel on Triglyceride, High-density Lipoprotein, and Coronary Heart Disease. JAMA. 1993;269:505-10.

Abbot RD , Wilson PF , Kannel WB , Castelli WP High density lipoprotein cholesterol, total cholesterol screening and myocardial infarction: the Framingham Study. Arteriosclerosis. 1988;8:207-11.

Yaari S. , Goldbourt U. , Even-Zohar S. , Neufeld HN Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10,000 men. Lancet. 1981;1:1011-5.

National Center for Health Statistics. Total Serum Cholesterol Levels of Adults 20 to 74 Years of Age: United States, 1976-1980 . Vital and Health Statistics, Series II, No. 236 (DHHS Publication No. (PHS) 86-1686), 1986.

Weissfeld JL , Weissfeld LA , Holloway JJ , Bernard AM A mathematical representation of the Expert Panel's guidelines for high blood cholesterol case-finding and treatment. Med Decis Making. 1990;10:135-46.

Weissfeld JL , Brock BM The National Cholesterol Education Project's definition of high risk . 1992 (unpublished manuscript).

10.

Morrison DF Multivariate Statistical Methods. New York: McGraw-Hill, 1976, p 92.

11.

Weissfeld JL , Holloway JJ Precision of blood cholesterol measurement and high blood cholesterol case-finding and treatment. J Clin Epidemiol. 1992;45:971-84.

12.

Oster G. , Epstein AM Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA. 1987;258:2381-7.

13.

Bookstein L. , Gidding SS , Donovan M. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Arch Intern Med. 1990;150:1653-7.

14.

Mogadam M. , Ahmed SW , Mensch AH , Godwin ID Within-person fluctuations of serum cholesterol and lipoproteins. Arch Intern Med. 1990;150:1645-8.

15.

Garber AM , Sox HC , Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med. 1989;110:622-39.

16.

Vital Statistics for the United States. Mortality (Part A) , vol. II. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers of Disease Control, National Center for Health Statistics, 1988.

17.

Shurtleff D. Some Characteristics Related to the Incidence of Cardiovascular Disease and Death. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease (section 30) (DHEW Publication No. [NIH] 47-539). Washington, DC: U.S. Department of Health, Education and Welfare, 1974.

18.

Caggiula AW , Cristakis G. , Ferrand M. , et al. The Multiple Risk Factor Intervention Trial (MRFIT): IV. Intervention on blood lipid. Prev Med. 1981;10:443-75.

19.

Neaton JD , Broste S. , Cohen L. , et al. The Multiple Risk Factor Intervention Trial (MRFIT): VII. A comparison of risk factor changes between two study groups. Prev Med. 1981;10:519-43.

20.

Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.

21.

Lipid Research Clinics Program. The Lipid Research Clinics Coronaiy Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74.

22.

Blankenhorn DH , Nessim SA , Johnson RL , et al. Beneficial effects of combined colestipol and niacin therapy on coronary aterosclerosis and coronary venous bypass grafts . JAMA. 1987;257: 3233-40.

23.

Kane JP , Malloy MJ , Tun P. , et al. Normalization of low-density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981;304:251-8.

24.

Illingworth DR Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med. 1984;101:598-604.

Designing a Simpler High Blood Cholesterol Case Detection Strategy

Abstract

Get full access to this article

References